WO2003099798A8 - Morpholinylmethylureas ccr-3 receptor antagonist - Google Patents
Morpholinylmethylureas ccr-3 receptor antagonistInfo
- Publication number
- WO2003099798A8 WO2003099798A8 PCT/EP2003/005597 EP0305597W WO03099798A8 WO 2003099798 A8 WO2003099798 A8 WO 2003099798A8 EP 0305597 W EP0305597 W EP 0305597W WO 03099798 A8 WO03099798 A8 WO 03099798A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- independently represent
- represent hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds of formula (I): wherein:R1 represents C3-8 cycloalkyl-Y1-, aryl-Y1-, heteroaryl-Y1-, aryl- G-Y1-, heteroaryl-G-Y1-, C1-6 alkyl-G-Y1-, J1-Y1-, R22R23N-Y1-, R22R23N-CO-Y1- or R24-CONR22-Y1-; Q represents -(CR19R20)(CR19aR20a)t-, wherein t represents an integer from 0 to 3;R2 and R3 independently represent hydrogen or C1-6 alkyl;X represents ethylene or a group of formula CReRf wherein Re and Rf independently represent hydrogen or C1-4 alkyl or Re and Rf may together with the carbon atom to which they are attached form a C3-8 cycloalkyl group; R4 and R5 independently represent hydrogen or C1-4 alkyl; Z represents a bond, CO, SO2, CR10R7(CH2)n, (CH2)nCR10R7, CR10R7(CH2)nO, CR10R7(CH2)nS, CR10R7(CH2)nCO, COCR10R7(CH2)n or SO2CR10R7(CH2)n; R6 represents aryl, heteroaryl or aryl-C2-6 alkenyl-; R7 represents hydrogen, C1-4 alkyl, CONR8R9 or COOC1-6 alkyl;a and b represent 1 or 2, such that a+b represents 2 or 3;G represents -S-, -SO2-, -SO2NR21, -NR21SO2 or -NR21-; n represents an integer from 0 to 4; J1 independently represents a moiety of formula (K): wherein X1 represents oxygen, NR11 or sulphur, X2 represents CH2, oxygen, NR12 or sulphur, m1 represents an integer from 1 to 3, m2 represents an integer from 1 to 3, provided that m1+m2 is in the range from 3 to 5, also provided that when both X1 and X2 represent oxygen, NR11, NR12 or sulphur, m1 and m2 must both not equal less than 2, wherein K is optionally substituted by one or more (eg. 1 or 2) -Y3-aryl, -Y3-heteroaryl, -Y3-CO-aryl, -Y3-CO-heteroaryl, -C1-6 alkyl, -Y3-COOC1-6 alkyl, -Y3-COC1-6 alkyl, -Y3-W, -Y3-CO-W, -Y3-NR15R16, -Y3-CONR15R16, hydroxy, oxo, -Y3-SO2NR15R16, -Y3-SO2C1-6 alkyl, -Y3-SO2aryl, -Y3-SO2heteroaryl, -Y3-NR13C1-6 alkyl, -Y3-NR13SO2C1-6 alkyl, -Y3-NR13CONR15R16, -Y3-NR13COOR14 or -Y3-OCONR15R16 groups, and is optionally fused to a monocyclic aryl or heteroaryl ring;R8, R9, R10, R11, R12, R13 and R14 independently represent hydrogen or C1-6 alkyl; R15 and R16 independently represent hydrogen or C1-6 alkyl or R15 and R16 together with the nitrogen atom to which they are attached may form a morpholine, piperidine or pyrrolidine ring; R17, R18, R19, R20, R19a, R20a, and R21 independently represent hydrogen or C1-4 alkyl; R22 and R23 independently represent hydrogen, C1-6 alkyl, C3-8 cycloalkyl or C3-8cycloalkylC1-6alkyl; R24 represents C1-6 alkyl, C3-8 cycloalkyl, aryl or heteroaryl; W represents a saturated or unsaturated, non-aromatic 5-7
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003240730A AU2003240730A1 (en) | 2002-05-29 | 2003-05-26 | Morpholinylmethylureas ccr-3 receptor antagonist |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212357.8A GB0212357D0 (en) | 2002-05-29 | 2002-05-29 | Novel compounds |
| GB0212357.8 | 2002-05-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003099798A1 WO2003099798A1 (en) | 2003-12-04 |
| WO2003099798A8 true WO2003099798A8 (en) | 2004-01-15 |
Family
ID=9937626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/005597 WO2003099798A1 (en) | 2002-05-29 | 2003-05-26 | Morpholinylmethylureas ccr-3 receptor antagonist |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003240730A1 (en) |
| GB (1) | GB0212357D0 (en) |
| WO (1) | WO2003099798A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1801108B9 (en) | 2004-09-08 | 2013-11-20 | Mitsubishi Tanabe Pharma Corporation | Morpholine compounds for the treatment of inflammations |
| DK3050574T3 (en) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Use of plerixafor for the treatment and / or prevention of acute exacerbations of chronic obstructive pulmonary disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031431A1 (en) * | 1994-05-18 | 1995-11-23 | Nisshin Flour Milling Co., Ltd. | Novel diaminomethylidene derivative |
| CA2372887A1 (en) * | 1999-05-25 | 2000-11-30 | Sepracor Inc. | Heterocyclic analgesic compounds and their use |
| AU2001290146A1 (en) * | 2000-09-29 | 2002-04-08 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
| AR035205A1 (en) * | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | USEFUL COMPOUNDS IN THE TREATMENT OF INFLAMMATORY DISEASES, PROCESS FOR PREPARATION, INTERMEDIARIES AND PHARMACEUTICAL COMPOSITIONS |
-
2002
- 2002-05-29 GB GBGB0212357.8A patent/GB0212357D0/en not_active Ceased
-
2003
- 2003-05-26 WO PCT/EP2003/005597 patent/WO2003099798A1/en not_active Application Discontinuation
- 2003-05-26 AU AU2003240730A patent/AU2003240730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099798A1 (en) | 2003-12-04 |
| AU2003240730A1 (en) | 2003-12-12 |
| GB0212357D0 (en) | 2002-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1101824A1 (en) | Aromatic compounds | |
| TW200510381A (en) | Novel 2-pyridinecarboxamide derivatives | |
| EP1679069A4 (en) | Novel piperidine derivative | |
| AU6257494A (en) | New 4-aminopyridines, process for preparing the same and medicaments containing the same | |
| PL373888A1 (en) | 3-heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | |
| EP1719761A4 (en) | Novel heterocyclic compound | |
| MXPA03001073A (en) | Compounds acting as melanocortin receptor ligands. | |
| WO2004039827A3 (en) | Glucocorticosteroids having a specific 17a-sidechain useful as antiinflammatory agents | |
| DE69624081D1 (en) | Matrix metalloprotease inhibitors | |
| DK1008592T3 (en) | Cyclic amide derivatives which inhibit cathepsin K | |
| DE60126649D1 (en) | COSMETIC COMPOSITION CONTAINING HETEROPOLYMERS AND A SOLID SUBSTANCE AND APPLICATION METHOD | |
| NO20070173L (en) | New connections | |
| MY148980A (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
| EP1741714A4 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
| WO2001070733A3 (en) | Di-substituted iminoheterocyclic compounds | |
| CA2203237A1 (en) | Aminotetrazole derivatives useful as nitric oxide synthase inhibitors | |
| WO2008136372A1 (en) | Photoresist base material and photoresist composition containing the same | |
| WO2008117871A1 (en) | Nitrogen-containing redox catalyst | |
| ES2016060A6 (en) | Butynylamine derivatives. | |
| WO2005023962A8 (en) | Photorefractive composition | |
| WO2003099798A8 (en) | Morpholinylmethylureas ccr-3 receptor antagonist | |
| NO944121L (en) | Epoksyravsyrederivater | |
| WO1999023092A3 (en) | 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them | |
| WO2003018538A1 (en) | Novel diarylalkene derivatives and novel diarylalkane derivatives | |
| FI920776A0 (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA 5- (SUBSTITUERAD AMINO) 1,2,4-TRIAZOLO- (1,5-A) PYRIMIDINDERIVAT. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| CFP | Corrected version of a pamphlet front page | ||
| CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 49/2003 UNDER (43) REPLACE "14 AUGUST 2003 (14.08.2003)" BY "4 DECEMBER 2003 (04.12.2003)" |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |